GBM Agile Archives - NFCR

GBM Agile

DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083’s Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research

SAN DIEGO, June 24, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies announced today it has received a $500,000 loan from the National Brain Tumor Society (NBTS) and the National Foundation for Cancer…...

Read more

GBM AGILE – Changing the Way We Fight Brain Cancer

GBM survival rates have not improved in any meaningful way in over 30 years despite desperate efforts. Glioblastoma Multiforme, referred to simply as GBM, is the deadliest type of brain cancer. GBM is widely regarded as incurable and universally fatal, killing 95% of patients within five years of diagnosis. It is…...

Read more

A Major Milestone! Global Coalition Launches World’s First Adaptive Clinical Trial Platform for Glioblastoma

Glioblastoma Multiforme (GBM) is the deadliest and most aggressive form of brain cancer for which there is currently no cure. This often-fatal brain cancer accounts for 45% of all malignant brain tumors and 12,000 cancer diagnoses per year in the United States, in addition to tens of thousands more around…...

Read more

Origin Cells of Glioblastoma May Have Been Identified

In what could be a major breakthrough, scientists at the Korea Advanced Institute of Science and Technology (KAIST) in South Korea claim to have identified the cellular origin of glioblastoma, a fast-growing type of central nervous system tumor that forms from supportive tissue of the brain and spinal cord. It…...

Read more

Global Coalition for Adaptive Research (GCAR) Names Gary Gordon Interim Chief Executive Officer

FOR IMMEDIATE RELEASE: November 8, 2018 CONTACT: Global Coalition for Adaptive Research Rachel Rosenstein-Sisson, Executive Assistant E-mail: rrosenstein.sisson@gcaresearch.org / Phone: 617-299-6471 National Foundation for Cancer Research Bradley Gillenwater, Senior Director for Global Programs & Communications E-mail: bgillenwater@nfcr.org / Phone: 301-961-9161 LEXINGTON, MA & ROCKVILLE, MD – Gary Gordon, M.D., Ph.D.,…...

Read more